Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


LifeCycle Pharma A/S Aiming to List on the Copenhagen Stock Exchange


Copenhagen, 16 October 2006 -- LifeCycle Pharma A/S (the 'Company'), an emerging pharmaceutical company based on an innovative product reformulation technology, is working towards listing the Company's shares on the Copenhagen Stock Exchange. LifeCycle Pharma has engaged Morgan Stanley and Danske Markets as financial advisers.

If the Company decides to list on the Copenhagen Stock Exchange, it is intended that the Company will raise funds to finance further development of the Company's products towards commercialisation.


LifeCycle Pharma's technology is designed to create improved drugs
LifeCycle Pharma is an emerging pharmaceutical company with a proprietary technology that has been designed to improve the quality of existing drugs by enhancing their release and absorption in the human body.

The Company has a late-stage product pipeline with a portfolio of six proprietary product candidates in various stages of clinical development. The most advanced product candidate has completed pivotal clinical studies and an application for market authorization was submitted to the US FDA in early October 2006.

All of LifeCycle Pharma's product candidates are based on the Company's MeltDose® technology which allows the Company to create new and improved versions of existing drugs. By applying the MeltDose technology to improve the efficacy of currently marketed drugs, LifeCycle Pharma believes it is able to develop products significantly faster and cheaper, and with a higher success rate compared with the traditional drug development.

The Company believes that its MeltDose technology not only improves the efficacy of drugs but may also through its ability to enhance patient absorption of the relevant drug reduce the side effects associated with such drug. The Company believes that the key advantages of its MeltDose technology include clear and measurable benefits such as lower dosing, reduced side effects and improved safety and patient compliance.

Applying its MeltDose technology, LifeCycle Pharma believes it is able to achieve reduced product development times and costs compared to companies whose drug development efforts are based on more conventional methods. The reason being that that by utilizing this technology to reformulate drugs, the Company is able to submit product approval filings based on regulatory procedures for currently marketed products.

Independent studies have shown that 30% of all marketed drugs have suboptimal uptake due to low water solubility. A large number of these drugs may be suitable candidates for the MeltDose reformulation technology. MeltDose may also be of significant value for new drugs for which low absorption of drug represents a barrier to full development.


LifeCycle Pharma's products close to the major markets
LifeCycle Pharma is focusing its efforts on six clinical drug candidates.

The MeltDose technology has allowed the Company to bring each of these product candidates from program initiation to first human dose (clinical studies) in less than 12 months. The typical development period from program initiation to regulatory submission for reformulated drugs is 3-5 years, while conventionally developed drugs typically require between 10 and 12 years before they can be submitted for regulatory approval.
1) LCP-FenoChol is the Company's most advanced product candidate and is currently expected to be launched in the US early in 2008. In early October 2006, the Company submitted an application for market authorization to the FDA in the US. The product is a cholesterol management drug developed to become the fenofibrate product with the lowest effective dose on the market. In 2005, sales of all fenofibrate drugs were approximately EUR 1.2 billion worldwide.

2) LCP-Feno is the Company's second fenofibrate product candidate, and has been designed as an AB-rated (substitutable) generic version of Tricor®, which is currently marketed by Ab


Publisher Contact Information:

LifeCycle Pharma A/S
+45 70 33 33 00
-

Company profile of LifeCycle Pharma A/S
Past press releases of LifeCycle Pharma A/S.

Data


26,368
Tech investments
From our Online Data Service
17,022
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.